Loading clinical trials...
Loading clinical trials...
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Advanced Solid Tumors
Conditions
Interventions
TP-3654
Locations
3
United States
MD Anderson
Houston, Texas, United States
Huntsman Cancer Institute
Salt Lake City, Utah, United States
University of Virginia
Charlottesville, Virginia, United States
Start Date
April 16, 2019
Primary Completion Date
March 30, 2021
Completion Date
July 8, 2021
Last Updated
November 14, 2023
NCT07177937
NCT07387068
NCT07360314
NCT07403721
NCT07539285
NCT07524348
Lead Sponsor
Sumitomo Pharma America, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions